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Diagnosis and Impact of Pancreatic Allograft Thrombosis
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Pancreatic allograft thrombosis (PAT) is a potentially catastrophic complication and remains one of the leading causes of non-immunologic allograft loss  ADDIN EN.CITE (1, 2). The incidence reported in the literature ranges from 1-40% and accounts for 29% of grafts lost within the first 6 months after transplantation  ADDIN EN.CITE (3, 4). Reported risk factors for PAT include donor age, body mass index (BMI), atherosclerosis, donation after circulatory death (DCD), death from cerebro-vascular accident and pre-mortem severe hypotension  ADDIN EN.CITE (5, 6). Recipient risk factors include vascular disease, thrombophilic state, history of previous thrombotic events, and hypotension in the intra- or post-operative period (3). Other significant risk factors include type of preservation solution (reduced risk with UW), prolonged cold ischaemia time (CIT) and technical factors during procurement and implantation  ADDIN EN.CITE (2, 7). Risk of graft loss secondary to PAT has been reported as 4-8% following simultaneous pancreas and kidney transplantation (SPK) and 10-12% following solitary pancreatic transplantation (SPT) (8). 
Imaging plays a vital role in the evaluation of the transplanted pancreas. The modalities commonly used are Doppler ultrasound (USS), contrast-enhanced ultrasound (CEUS), computed tomography (CT), CT angiography, MRI (magnetic resonance imaging) and MR angiography  ADDIN EN.CITE (9-12). Vascular evaluation on imaging following pancreas transplant is challenging due to the multiple anastomoses (4 or more), tortuous nature of graft vessels and parenchymal oedema related to surgery or pancreatitis. Overlying bowel gas may make ultrasound imaging suboptimal  ADDIN EN.CITE (13-15). 
Allograft thrombosis may affect arteries or veins, or sometimes both. Although there is no consensus on the classification or reporting of PAT, it is generally categorised as either complete or partial  ADDIN EN.CITE (16). Complete occlusion usually results in graft loss, unless thrombectomy or thrombolysis are undertaken soon after onset  ADDIN EN.CITE (17-20). Conversely, there is some evidence to suggest higher likelihood of pancreas allograft salvage with anticoagulation alone after partial thrombosis, although other interventions are occasionally required  ADDIN EN.CITE (21, 22). Outcomes following partial or complete occlusion of either splenic or superior mesenteric veins are better than complete occlusion of the main portal vein  ADDIN EN.CITE (23). Collateral arterial circulation may prevent infarction in cases of partial and occasionally complete PAT  ADDIN EN.CITE (24). 
There is currently no consensus on the optimal strategy for the prevention and management of PAT. Post-operative prophylaxis using low-dose heparin infusion has been shown to reduce the thrombosis rate, but with a consequent increase in the number of bleeding events and need for re-laparotomy  ADDIN EN.CITE (25-27). 
The aim of the current study was to analyse the incidence and management of PAT in a single centre and to evaluate risk factors for PAT. We also propose a CT grading system of PAT and a management algorithm based on the grade of thrombosis.

MATERIALS AND METHODS
Following institutional review board approval, a retrospective review of consecutive pancreas allograft transplants performed at our centre between January 2009 and April 2014 was carried out. Data regarding donor and recipient demographics, operative details and outcomes were collected from a prospectively maintained electronic database. The outcomes reviewed were the incidence of PAT, graft and patient survival, post-operative complications and length of post-operative hospital stay. Patients had workup for prothrombotic tendancies if a prior thrombotic event was identified. 
The incidence, risk factors and consequences of PAT were examined using two methods. The first was a retrospective review of clinical data as recorded in the database during the original patient care episode, including incidence of thrombosis, graft and recipient outcomes (labelled ‘original diagnosis’). In the second stage, the first post-operative triple phase CT of the abdomen and pelvis (CTAP) of all pancreas transplant recipients were independently reviewed by two senior radiologists who were blinded to the initial CT report and the patient outcomes. Discrepancies were resolved by consensus. This ‘retrospective diagnosis’ was used to definitively grade the thromboses and formulate a management algorithm. The pancreatic allograft arteries and veins were graded as per the ‘new’ grading system (Table 1). Representative cross-sectional images demonstrating the different grades of thrombosis are shown in Figure 1. 
Acute rejection was defined as rejection on kidney or pancreas biopsy. Graft pancreatitis was defined as peri-pancreatic oedema and/or inflammatory change on CT imaging. 
Operative technique
Back-bench preparation of the pancreatic graft involved removal of spleen, ligation of all the distal mesenteric vessels and anastomosis of a donor iliac Y-graft to the graft superior mesenteric and splenic arteries. The pancreas was placed in the right iliac fossa intraperitoneally through a midline incision, with anastomosis of the portal vein to the inferior vena cava and the donor iliac artery Y-graft to the recipient common iliac artery. Enteric drainage was via a Roux-en-Y duodeno-enterostomy. Feeding jejunostomy was inserted in most cases and prophylactic appendicectomy and cholecystectomy (the latter, if pre-operative USS demonstrated sludge/gallstones) were performed.  All recipients were started on intravenous epoprostenol 4.0 ng/kg/min (Flolan®) immediately after reperfusion and continued for a period of 5 days or discontinued earlier in case of haemodynamic instability or bleeding. Those patients who were not on Aspirin 75 mg once daily, were started on it at discharge or earlier if platelet count >500 x 109 /L. The standard immunosuppression protocol was induction with Alemtuzumab (CD52 monoclonal antibody; Campath 1H®) 30 mg subcutaneously. Maintenance immunosuppression was steroid-free with Tacrolimus 0.05 mg/kg twice daily started on the first post-operative day (trough concentration 8-12 ng/ml) and mycophenolate mofetil started at 500 mg twice daily on post-operative day 7. 
CT imaging
Triple phase CTAP was performed using 64 or 256 section CT systems (Siemens AG Healthcare). Unenhanced imaging of the abdomen was performed to localise the pancreatic graft followed by early arterial phase imaging of the pancreatic and renal grafts and portal phase imaging of the abdomen and pelvis. 100mls of iopamidol non-ionic contrast (Niopam 300, Bracco, High Wycombe, Bucks, UK) was administered at a rate of 3 mls per second.  Images were reconstructed and reviewed at 2mm section thickness on the picture archive and communication system (PACS GE). The triple phase CT scans were performed for clinical/biochemical reasons and no routine or protocol scans were performed. Intravenous fluid rehydration was considered in recipients with a raised creatinine of greater than 150 µmol/L. Routine USS is performed to evaluate the renal allograft, routine USS of the pancreatic graft is not performed in our unit.
Statistical analysis
Categorical variables are expressed as frequency (%) and continuous variables as median (range). Categorical variables were analysed by Fisher’s exact or chi-square test and continuous variables by unpaired student t-test, Mann-Whitney U test or other non-parametric tests. Bonferroni correction was used for multiple comparisons. The variables significant on univariate analysis were subjected to multivariate logistic regression analysis. Kaplan-Meier survival curves were studied using log-rank statistics [(SPSS 20.0 (Chicago, IL, USA)].

RESULTS
103 consecutive pancreatic transplants were performed during the study period. The mean follow-up period was 53.7 months (range 21.7 to 83.3 months). Twenty-four recipients (23.3%) were diagnosed with PAT (original diagnosis), of which four patients had this diagnosis confirmed on laparotomy, while one patient had a negative laparotomy. The thromboses were initially reported as arterial (n=11, 10.7%), venous (n=9, 8.7%) or both (n=4, 3.9%). Of the arterial thromboses, fourteen were grade 1 or 2 and one was grade 3. Of the venous thromboses, eight were grade 1 or 2 and five were grade 3. Three patients required intra-operative revision of anastomosis for thrombosis during the index transplant operation; two of which developed post-operative thrombosis and hence were included in the thrombosis group.
The patients who had thrombosis as their original diagnosis (n=24, 23.3%) were compared with those who did not have thrombosis (n=79, 76.7%) (Tables 2-5).
Donor characteristics
There was no difference between the two groups in terms of donor age, gender, ethnicity, weight and BMI (Table 2). There were numerically more DBD (donation after brainstem death) donors in the thrombosis group (n=19, 79.2%) compared with the no thrombosis group (n=50, 63.3%), but this was not statistically significant (p=0.107). 
Recipient characteristics
There was no difference between the two groups in terms of recipient age, gender, weight, BMI or previous thrombotic events (Table 3). Three patients (12.5%) in the thrombosis group had previous failed transplants (all SPK pancreases: two failed due to recurrence of diabetes and one due to venous thrombosis) in comparison to 4 patients (5.1%) in the no thrombosis group (2 SPKs [lost due to venous thrombosis and chronic rejection] and 2 kidney alone transplants) (p=0.349). 
Operative characteristics
In total, 4 of 5 (80%) pancreas after kidney or SPK (PAK/PASPK) transplants had thrombosis post-operatively (p<0.001) [Table 4]. Only one recipient had portal vein reconstruction at the time of transplantation using an 8mm extension graft; he subsequently developed portal venous thrombosis. Two patients (8.3%) in the thrombosis group had intra-operative thrombosis and the portal vein anastomoses were re-done, in comparison to one patient (1.3%) in the no thrombosis group in whom the arterial anastomosis was re-done (p=0.135). 

Recipient outcomes
Recipient outcomes for the two groups are shown in table 5. The retrospective grading of CTs in patients with the original diagnosis of thrombosis were: arterial thrombosis - grade 1 (n=10), grade 2 (n=4) and grade 3 (n=1); venous thrombosis - grade 1 (n=5), grade 2 (n=3) and grade 3 (n=4). The median time of thrombosis diagnosis after transplant was 5 days (range 0-120 days). Of the 24 patients with an original diagnosis of thrombosis, 23 had a CT diagnosis and one patient underwent surgical exploration without a CT scan. This patient, who was noted to be at high risk of venous thrombosis at the initial implant surgery and was anti-coagulated in the immediate post-operative period, was re-explored on post-operative day 1 with removal of splenic vein thrombus. With continuing hyperglycemia and worsening lactate, the patient was re-explored again at 48 hours post-transplant and graft pancreatectomy was performed. 
All patients with an original diagnosis of thrombosis were therapeutically anticoagulated with dalteparin (140 units/kg/day split into two doses at 12 hours interval) in the first instance followed by warfarin for a period of 3 months (target INR 2-2.5). Patients who underwent re-exploration were anticoagulated after exploration surgery, unless graft pancreatectomy (3 patients) was performed.
There were no contrast induced allergic reactions in our study cohort. 81 patients had at least one post-operative CT during the study period. Serial Cr results were available for 67 of these patients. 12 patients had acute rise in Cr following CT scans, in keeping with contrast induced acute injury (CI AKI), although 7 patients were on dialysis at the time. An alternative possible explanation for the rise in Cr was identified in all 5 patients: one patient was diagnosed with rejection, one with haemorrhage, one with renal arterial flow abnormality on USS, and two with abdominal pain +/- pyrexia. The renal function recovered in all 12 patients with rehydration.
Arterial thrombosis 
One patient with grade 1 arterial thrombosis and extrinsic compression of the portal vein on CT was re-explored and no thrombus was seen within the artery, but there was severe pancreatitis of the allograft. The patient subsequently had a graft pancreatectomy on post-operative day 46 due to abscess formation and severe pancreatitis. One other patient with grade 1 arterial thrombosis (with grade 3 PVT) was re-explored and PV thrombus was removed. The graft failed on post-operative day 144 day due to chronic rejection (biopsy proven). All other patients with arterial thrombosis [including grade 2 (n=4) and grade 3 (n=1)] were anticoagulated and had functioning grafts at the end of study follow-up. The grade 3 arterial thrombosis patient’s CT on retrospective review was reported as no thrombosis and only short-segment stricture of splenic artery.
Venous thrombosis  
All patients with grade 1 (n=5) venous thrombosis were anticoagulated and had functioning grafts at the end of study follow-up. The only patient who had a PV extension graft, had a CT diagnosis of grade 2 venous thrombosis on post-operative day 5. Re-exploration and thrombectomy did not improve graft perfusion and pancreatectomy was performed.  Another patient with grade 2 venous thrombosis was re-explored on post-operative day 1 and portal vein thrombus was removed; the graft was functioning at the end of study follow-up. One other patient with grade 3 venous thrombosis on CT imaging on post-operative day 3 was managed with anti-coagulation initially, but was re-explored on day 9 due to haemorrhage and the graft was subsequently removed on day 11 due to severe haemorrhage and PVT.  All other patients with grade 2 (n=1) and 3 (n=2) venous thrombosis were managed with anticoagulation and had a functioning graft at the end of study follow-up. 
Post-operative complications and length of hospital stay
Eight patients (33.3%) in the thrombosis group were re-explored for bleeding (3 pre-anticoagulation and 5 post-anticoagulation), whereas 12 (15.2%) were re-explored for bleeding in the control (no thrombosis) group (p=0.074). There were 21 early (within 30 days) complications in 13 patients in the thrombosis group and 39 complications in 31 patients in the control group (p=0.241) [Table 5]. The median length of post-operative stay (21 days vs. 15 days; p=0.001), the number of acute rejection episodes [8 (33.3%) vs. 7 (8.9%); p=0.006] and the likelihood of CT finding of pancreatitis [12 (50.0%) vs. 11 (13.9%); p<0.001] were significantly higher in the thrombosis group in comparison to the no thrombosis group (Table 5). 
Risk factors for PAT
On multivariate analysis, PASPK/PAK transplant (OR 1.09, CI 1.01-0.97, p=0.047), acute rejection (OR 1.25, CI 1.07-1.90, p=0.034) and CT finding of pancreatitis (OR 1.23, CI 1.08-1.72, p=0.011) were risk factors for PAT (Table 6).  The risk of vascular thrombosis was 9% higher with PASPK/PAK transplant in comparison to SPK transplant, 25% higher when there was acute rejection (although most cases of thrombosis were diagnoses early and before the diagnosis of rejection) and 23% higher when there were CT findings of allograft pancreatitis. 
Graft and patient survival
There were 6 (25.0%) graft losses in the thrombosis group with three grafts lost within 30 days due to portal vein thrombosis resulting in graft pancreatectomy on day 2, 5 and 11. The other three graft losses were due to severe pancreatitis with abscess formation in one patient, and biopsy proven chronic rejection in two patients. There were 3 (3.8%) graft losses in the control group, two due to chronic rejection and one due to recurrence of “autoimmune” diabetes mellitus (Table 5). The 1, 3 and 5-year death-censored graft survival for thrombosis and no thrombosis groups were 75%, 75% and 75% versus 100%, 90% and 90% respectively (log-rank p<0.0001) [Figure 2]. There was no difference in patient survival between the two groups [1, 3 and 5 year were 98%, 96% and 94% in each group] (Figure 3). None of the patient deaths in the study groups were directly related to PAT (Table 5). 
Risk factors for graft loss
On univariate analysis, recipient anastomosis time (48 ± 11 mins in graft loss group versus 38 ± 9 mins in control group; p=0.001) and PAT (66.7% in graft loss group versus 19.1% in control group; p=0.005) were statistically significant predictors of graft loss. On multivariate analysis, PAT was the only significant risk factor for graft loss (OR 1.17, 95% CI 1.04-1.83, P=0.028). 
Independent retrospective review of CT images
Over the study period, 81 CT examinations were reported during the index admission. In total, 16 different senior radiologists reported the CT images over the study period. On independent review of the CTs, previously unreported thromboses (additional thromboses) were identified by both review radiologists. In consensus, the review radiologists identified a total of 28 new thromboses: Seventeen grade 1 arterial, two grade 2 arterial, five grade 1 venous and four grade 2 venous thromboses. No new grade 3 arterial or venous thromboses were identified on review (Table 7). Four patients who were initially reported to have thrombosis were subsequently reviewed as having no thrombosis. The thrombosis grade for these four patients on initial reports were grade 1 arterial, grade 3 arterial and two patients with grade 1 venous. 
Using the new retrospective diagnoses, we repeated the earlier analysis that is shown in table 1-4 using the original diagnoses. Univariate analysis comparing those who had thrombosis on retrospective CT review (n=53) with those who had no thrombosis (n=28), demonstrated no significant predisposing factors for thrombosis (Supplementary tables 1-4). 
Outcomes based on retrospective review of CT images
Based on the retrospective review, patients were divided into four distinct groups according to the presence or absence of thrombosis (as a consensus of radiologist 1 and 2) and whether or not the recipients were anticoagulated. The retrospective review gave us an opportunity to compare outcomes in these groups, in a manner that would not be possible prospectively outside of a randomised controlled trial. Moreover, if we assume that the ‘new’ thromboses diagnosed only on retrospective review were originally not reported at random, this approach reduces (but does not eliminate) bias. 
Twenty-six patients were identified to have thrombosis on retrospective CT review but were previously not anticoagulated (T-NAC). Eighteen patients with thrombosis on retrospective review were anticoagulated (T-AC). Compared to the T-NAC group, T-AC group demonstrated trends towards more re-exploration for bleeding [7 (38.9%) vs. 3 (11.5%); p=0.064], longer median length of stay [21 days vs. 15 days; p=0.077] and more peri-pancreatic oedema and/or inflammatory changes on CT [10 (55.5%) vs. 4 (15.4%); p=0.008]. There were two grafts lost in the T-AC group due to portal vein thrombosis (Table 8 and Figure 4). 
When comparing the T-NAC group (n=26) with the T-AC group with only grade 1 and 2 thrombosis (n=11), there was no difference in re-exploration for bleeding [2 post-anticoagulation (18.2%) vs. 3 (11.5%); p=0.210] and median length of stay [17 days vs. 15 days; p=0.374]. There was no graft loss due to thrombosis in those with T-NAC and T-AC with grade 1 and 2 thrombosis only (Table 8). There was also no difference in graft and patient survival on comparing those who were anticoagulated for grade 1 and 2 thrombosis and those who were not anticoagulated (Figures 5 and 6). 
Based on these findings, an algorithm for the management of thrombosis based on new CT grading system is presented in Figure 7.
Evolution of thrombosis on retrospective review of CT images
To determine if anticoagulation influences the evolution of grade 1 and 2 thromboses, we compared late CT images in the T-AC and TNAC groups (table 9). Retrospective review of CT images at 3 months of those who were anticoagulated for thrombosis demonstrated a reduction in grade of thrombosis in 5 out of 8 patients and an increase in thrombosis grade in 2 patients. Review of last CT scans done at a median of 530 days post-transplant showed decrease in thrombosis grade in 5 out of 7 and increase in grade in 2 patients. In those patients who were not anticoagulated for thrombosis, CT scans at 3 months showed 2 out of 5 patients with reduction in grade of thrombosis and 1 patient with increase in thrombosis grade. Further CT scans at median of 670 days showed 10 out of 15 patients with reduction in grade of thrombosis and 2 with increase in thrombosis grade. 

DISCUSSION 	
The incidence of PAT in our centre is 23.3% (n=24). The rate is high because we have included grade 1 thrombosis (peripheral thrombus), which forms majority of our thrombosis (45.8%; n=11). We believe many of these are not reported in previous publications. Only 5.8% of recipients in our series were diagnosed with occlusive (grade 3) thrombosis. Moreover, the incidence of graft loss secondary to thrombosis was only 2.9%  ADDIN EN.CITE (5, 28). While managements of recipients with PAT must be primarily based on individual clinical circumstances, we believe that our analysis can potentially inform and enhance evidence-based clinical decision making.  Based on our proposed grading system, henceforth termed the Cambridge Pancreas Allograft Thrombosis (CPAT) grading, our data suggest that grade 1 and 2 arterial thrombosis and grade 1 venous thrombosis can be managed safely without formal anticoagulation. Although we report 17% higher risk of graft loss with thrombosis, all of the graft losses in our cohort were due to grade 2 or 3 thrombosis and grade 1 thrombosis had no effect on graft or patient survival. The risk factors for PAT in our cohort were pancreas transplantation into a non uraemic patient, acute rejection and pancreatitis on CT, similar to previous published literature (29, 30). 
The important findings from our study are that arterial thrombosis presented late (median 5 days) when compared to venous thrombosis (median 3 days) and most cases of arterial thrombosis could be managed with anticoagulation alone. In comparison, more than half of our venous thromboses were diagnosed within the first 72 hours and prompted re-exploration; there was higher risk of graft loss when a grade 3 thrombosis was present. Arterial thrombosis including both partial (grade 1 and 2) and complete (grade 3) were managed with anticoagulation alone in our cohort with no graft loss, albeit the grade 3 thrombosis on retrospective review was reported as no thrombosis. Only one graft was re-explored for grade 1 arterial thrombosis (thrombus distally in the graft), but there was also concern about extrinsic compression of the portal vein on this patient’s CT scan, which contributed significantly to the decision to re-explore. At re-exploration, there was only evidence of severe graft pancreatitis and no arterial thrombosis. This was the only negative laparotomy in our study cohort. On retrospective review of this patient’s CT scan, radiologist 1 reported no arterial thrombosis and radiologist 2 reported a grade 1 arterial thrombosis. Fridell et al, in a retrospective review of 35 re-explorations for thrombosis in 345 transplants over a 7 year period, reported a negative laparotomy rate of 43%  ADDIN EN.CITE (18).  
The proposed CPAT grading system helps clinicians make decisions on which grafts may require re-exploration and which can be managed with anticoagulation alone. The retrospective review of the CT images allowed us to compare two groups – one therapeutically anticoagulated for grade 1 and 2 thrombosis and one managed conservatively. Because the diagnoses of thrombosis in the non-anticoagulated group were not reported at random, this reduces potential bias arising from allocation of patients to the two groups. In this study, therefore, patients were in effect ‘inadvertently randomised’ into anti-coagulation and conservative groups at the time of the index admission.  Importantly, we were able to compare outcomes in the two groups where the CPAT grades of the thrombosis were comparable (grades 1 and 2). Those who were managed without anticoagulation had similar graft and patient survival. Importantly the morbidities associated with anticoagulation such as re-exploration for bleeding were numerically less in the non-anticoagulated group (11.5% vs. 36.4%; p=0.201) and hence the length of stay was shorter (15 days vs. 17 days; p=0.374). An ideal prospective study would be to randomise patients with grade 1 and 2 (partial thrombosis) into anticoagulation versus no-anticoagulation arms. Such a study would need large number of transplants to adequately power the study and may not have clinical equipoise to justify such randomisation. Although the CPAT grading system has been used to report CT studies, we believe the same grading system could be applicable for USS or CEUS or MR reporting of PAT.
Management of PAT without anticoagulation (except aspirin) has been reported previously with no deleterious effects on the graft. Ciancio et al reported six patients with partial PAT of the splenic vein, who were started on aspirin 81mg once daily and followed up with serial Doppler USS. None progressed to complete thrombosis and all had functioning graft at the end of follow-up  ADDIN EN.CITE (31). Delis et al managed partial venous thrombosis (n=10) with aspirin alone and showed no progression of thrombosis. They reported recanalisation of the thrombosed veins on follow-up imaging and overall, there was no effect on graft survival (32). Our retrospective review of images at 3 months and subsequently showed that majority of patients who were not anticoagulated for thrombosis, had a reduction in grade of thrombosis to no thrombosis or lower grade thrombosis. This is in keeping with our suggestion that formal anticoagulation with LMWH is unnecessary in grade 1 and 2 arterial and grade 1 venous thrombosis.  Thromboelastography (TEG) directed anticoagulation may have a role in identifying patients who need anticoagulation in the post-operative period [33]. 
The major strength of our study is the inclusion of unselected, consecutive patients from a single centre. The retrospective nature of the study and the relatively small number of patients are obvious limitations. There were no changes in the pre-operative assessment of the recipients, immunosuppression protocols or post-operative management during the study period, thereby reducing the bias associated with the retrospective studies. Triple phase CT was requested in the post-operative period to rule out thrombosis if there was a rise in pancreatic enzymes (amylase or lipase) or raised glucose (>10mmol/L). Hence these scans were not driven by any routine protocol. However, it is difficult to ascertain if those who did not have CT (one-fifth of our patients) may have had subclinical thrombosis, hence our results may not give a true picture of the incidence of thrombosis. It is also likely that too many CT scans could have picked up peripheral thrombosis (grade 1), which would not have altered clinical outcome, but resulted in therapeutic anticoagulation in our cohort. The retrospective independent and blinded review of CT examinations by two radiologists gave us a specific cohort, allowing comparison of those who had grade 1 and 2 thromboses and were managed with and without anticoagulation. Although retrospective combined review of CT examinations resulted in a greater number of small-volume thromboses being identified, those except central occlusive thromboses in either the arterial or venous system can be managed without anticoagulation.

Conclusion
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